Characteristics, treatment patterns and outcomes of patients with small cell lung cancer--a retrospective single institution analysis
| Autor: | Ulrich Gatzemeier, Martin Reck, Andreas Hermes, Benjamin Waschki |
|---|---|
| Rok vydání: | 2009 |
| Předmět: |
Pulmonary and Respiratory Medicine
Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Antineoplastic Agents Small-cell carcinoma Internal medicine medicine Humans Carcinoma Small Cell Lung cancer Survival analysis Aged Neoplasm Staging Retrospective Studies Aged 80 and over Performance status business.industry Cancer Retrospective cohort study Middle Aged medicine.disease Prognosis Survival Analysis Surgery Treatment Outcome Oncology Female Prophylactic cranial irradiation business Progressive disease |
| Zdroj: | Lung cancer (Amsterdam, Netherlands). 71(3) |
| ISSN: | 1872-8332 |
| Popis: | Purpose The aim of this retrospective study is to present data on patient characteristics, treatment patterns, and treatment results in an unselected contemporary patient population with small cell lung cancer (SCLC) in limited disease (LD) and extensive disease stage (ED). Patients and methods From June 2004 to December 2008, our electronic database including all in-patient and out-patient contacts was searched for patients with newly diagnosed lung cancer. 397 patients were found having SCLC. We collected data on patient characteristics, chemotherapy, side effects, response on treatment and survival. Results 39% of all patients had LD SCLC. Median age was 63 years. The response rate (RR) reached 76%. Stable disease was the result of first line therapy in 16%. Consecutive thoracic radiotherapy was given in 72%. Additional prophylactic cranial irradiation (PCI) was administered to 33%. 43% received second line therapy. Median survival was 18.8 months. In 61% of cases, ED SCLC was diagnosed. Median age was 61 years. Main metastatic sites were liver, bone, brain and adrenal glands. RR was 69%. Stable disease and progressive disease were the result of first line chemotherapy both in 12%. 15% received palliative cranial irradiation, 3% PCI. 51% were treated with second line therapy. Median survival reached 10.6 months. Conclusion We provide a comprehensive analysis of a contemporary patient population. Treatment patterns and survival data fit well in the context of current international trials on more selected patients. Multivariate analyses confirmed extend of disease, performance status and LDH serum levels as independent prognostic factors for survival. Age and gender reached no statistical significance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect